Skip to main content

Diabetes Drug News

Diabetes Drugs are responsible for helping to decrease blood sugar levels so that you can try to stay in a healthier range and help avoid serious complications.

Metformin     Insulin     SGLT-2     GLP-1     DPP-4     Combo drugs     Sulfonylureas     TZDs

Debates in type 1 diabetes – what is the future of technology and what is a “cure"? Part three of our interview with David Panzirer and Dana Ball.
On June 17, Boehringer Ingelheim (BI) and Lilly announced the resubmission to the FDA of the SGLT-2 inhibitor Jardiance (empagliflozin) for the treatment of type 2...
On June 5, Xeris Pharmaceuticals announced that the first patient had been dosed in its phase 2 clinical trial , which is testing “mini-dose” glucagon for the treatment...
On June 27, the FDA approved MannKind’s Afrezza for type 1 and type 2 diabetes, a new rapid-acting inhaled insulin. We’ve been following this story for years in diaTribe...
On April 25, J&J announced that a metformin/Invokana (canagliflozin) fixed-dose combination pill called Vokanamet was approved in Europe. This makes the combined...
In February, Johnson and Johnson announced that its SGLT-2 inhibitor for type 2 diabetes, Invokana (canagliflozin), will undergo trials as a treatment for diabetic...
The Future of Type 1 Diabetes – what challenges and promises lie ahead? Part two of our interview with David Panzirer and Dana Ball.
On April 24, Hyperion Therapeutics announced that it would acquire Andromeda Biotech. Andromeda is focused on the development of a first-in-class immune therapy for new...
At the end of March, encouraging news about Takeda’s once-daily pill for type 2 diabetes, Nesina (alogliptin), circulated at the American College of Cardiology (ACC)...
On April 15, the FDA approved GlaxoSmithKline’s once-weekly GLP-1 agonist Tanzeum (albiglutide) for type 2 diabetes, which makes it the second once-weekly GLP-1 agonist...
On April 3, an FDA Advisory Committee voted an overwhelming 13-1 in favor of approving MannKind’s ultra-rapid-acting inhaled insulin Afrezza for type 1 diabetes. The...
On February 11, the FDA released a Drug Safety Communication requesting data from the widely publicized cardiovascular outcomes trial for Onglyza (saxagliptin). The...
Do you ever wonder why there aren’t cheaper “generic” insulin products available? This may soon change as the patents for branded insulin begin to expire. In fact, the...
Cellnovo recently launched its mobile-enabled insulin pump system in the UK, after receiving very positive feedback from a usability study that began in the UK in...
On March 3, AstraZeneca announced FDA approval for the Bydureon dual-chambered pen (once-weekly exenatide) to improve glycemic control in people with type 2. The device...
MannKind’s inhalable ultra-rapid-acting insulin Afrezza has its day at the FDA – find out what it can do for patients and how to speak up!
On January 22, AstraZeneca (AZ) announced the approval of Xigduo (dapagliflozin and metformin hydrochloride) for the treatment of type 2 diabetes in Europe. The drug is...
On January 21, Glooko and Joslin announced a partnership to develop a new web/mobile-based diabetes management platform. The system will combine a “Virtual Joslin”...
The top three things I’d like to see in 2014 – updates on CGM, mHealth, and combination therapy.

Pages